Research Article
Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
Table 4
Adverse events considered to be treatment related by investigators (NCI-CTC v4.0).
| Adverse events | Number of patients with events (%) | PD-1 blockade alone (n = 38) | PD-1 blockade-based combination (n = 13) | Total | Grade 3-4 | Total | Grade 3-4 |
| Any | 21 (55.3%) | 1 (2.6%) | 11 (84.6%) | 4 (30.8%) | Elevated transaminase | 5 (13.2%) | 0 (0%) | 5 (38.5%) | 3 (23.1%) | Elevated bilirubin | 1 (2.6%) | 0 (0%) | 3 (23.1%) | 0 (0%) | Anemia | 1 (2.6%) | 0 (0%) | 1 (7.7%) | 0 (0%) | Leukopenia | 2 (5.3%) | 0 (0%) | 1 (7.7%) | 0 (0%) | Hypothyroidism | 4 (10.5%) | 0 (0%) | 2 (15.4%) | 0 (0%) | Hyperthyroidism | 2 (5.3%) | 0 (0%) | 2 (15.4%) | 0 (0%) | Elevated myocardial enzyme | 1 (2.6%) | 0 (0%) | 3 (23.1%) | 0 (0%) | Elevated creatinine | 1 (2.6%) | 0 (0%) | 1 (7.7%) | 0 (0%) | Pyrexia | 2 (5.3%) | 0 (0%) | 4 (30.8%) | 0 (0%) | Rash | 1 (2.6%) | 0 (0%) | 1 (7.7%) | 0 (0%) | Itchy skin | 2 (5.3%) | 0 (0%) | 1 (7.7%) | 0 (0%) | Fatigue | 3 (7.9%) | 0 (0%) | 2 (15.4%) | 0 (0%) | Vitiligo | 1 (2.6%) | 0 (0%) | 1 (7.7%) | 0 (0%) | Hypertension | 1 (2.6%) | 1 (2.6%) | 4 (40.8%) | 0 (0%) | Uveitis | 0 (0%) | 0 (0%) | 1 (7.7%) | 1 (7.7%) |
|
|